Tocilizumab for Acute Chest Syndrome

Exclusion Criteria

• •Pregnant patients or breastfeeding mothers.
• •Prior treatment with gene therapy or a stem cell transplant.
• •Current enrollment in a clinical trial involving an FDA-regulated drug or biologic.
• •Current neutropenia (absolute neutrophil count \< 1000/mm\^3)
• •Current thrombocytopenia (platelet count \< 50,000 mm\^3)
• •Aspartate aminotransferase (AST) or alanine transaminase (ALT) \> 10 times the upper limit of normal (ULN)
• •History of tuberculosis (TB).
• •Positive purified protein derivative (PPD) TB screening test.
• •On active therapy with a Bruton's tyrosine kinase-targeted agent, which include the following: Acalabrutinib, Ibrutinib, Zanubrutinib
• •On active therapy with a JAK2-targeted agent, which include the following: Baricitinib, Ruxolitinib, Tofacitinib, Upadacitinib
• •Any of the following biologic immunosuppressive agent (and any biosimilar versions thereof) administered in the past 6 months:
• •Abatacept, Adalimumab, Alemtuzumab, Atezolizumab, Belimumab, Blinatumomab, Brentuximab, Certolizumab, Daratumumab, Durvalumab, Eculizumab, Elotuzumab, Etanercept, Gemtuzumab, Golimumab, Ibritumomab, Infliximab, Inotuzumab, Ipilimumab, Ixekizumab, Moxetumomab, Nivolumab, Obinutuzumab, Ocrelizumab, Ofatumumab, Pembrolizumab, Polatuzumab, Rituximab, Sarilumab, Secukinumab, Tocilizumab, Tositumumab, Tremelimumab, Urelumab, Ustekinumab